Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. - Wikidata - wikimedia - TriplyDB

Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.

Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.

http://www.wikidata.org/entity/Q34049077

about

Recent update in HIV vaccine development The role of Fc-FcγR interactions in IgG-mediated microbial neutralization Structural insights on the role of antibodies in HIV-1 vaccine and therapy Antibody responses to envelope glycoproteins in HIV-1 infection HIV therapeutic vaccines: moving towards a functional cure Vaccines for the 21st century HIV broadly neutralizing antibody targets A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies Broadly Neutralizing Antibodies for HIV Eradication Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design Antibodies for HIV prevention in young women HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth An efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodies Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies.Engineering antibody-like inhibitors to prevent and treat HIV-1 infection.Back to the future: recombinant polyclonal antibody therapeutics.Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection Early antibody therapy can induce long-lasting immunity to SHIV Which Antibody Functions are Important for an HIV Vaccine?Antibody 10-1074 suppresses viremia in HIV-1-infected individuals Immunologic strategies for HIV-1 remission and eradication.Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry.Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes.AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.

P2860

Q26766628-632B4E83-3C98-45FA-AD1A-A56F5875B413 Q26797466-76D3722B-28BB-4DEB-A53C-378C3D1B5801 Q26829461-30476061-8AA8-439B-A4A8-AFF283ED9954 Q26991572-B33BAD11-B07F-4378-B24D-9425A1D61770 Q27002180-4A7BCD97-B1DC-4679-8CF2-3157A55A4E78 Q27007529-67948975-C73E-45ED-ACE0-E89DB4B95EFB Q27026662-F9C3A022-F5EE-4A49-BF31-9308B303AA35 Q27302081-FCAD74CD-EF29-45E0-A601-7AA7740108A1 Q27324184-7E50AB35-CE02-4109-80F2-3840AF0776DA Q27683540-2B24103B-4BA9-4C75-815A-64DAF2088768 Q27683553-94B07AB2-6470-4F77-A852-D47A0B8DD3B9 Q28066335-AA622C23-C471-4934-8ADC-4A1DB09DEAFC Q28068018-223100FA-77F8-41EC-98CB-79ED7145F035 Q28068946-FF5687F0-1C54-4E5F-AA1C-00FA82879D0F Q28073939-EF012639-A808-4851-BC9A-89F92ACC18BD Q28075274-2B4D3FE8-D637-45A9-8173-787075D45A0F Q28082033-FC8387BF-6982-4AB3-963D-93D129FB7E4B Q28086826-24EF06D8-12A9-4FD1-852B-91CB59C91210 Q28545185-598415C1-F3A7-4F17-AEED-3B9B719C3E62 Q30352300-AFF5379D-B2FB-42A1-A8C9-C90007D705C6 Q30490945-77247162-3600-4F2B-BE76-0C2943CA536D Q33412776-7B1F7083-2BB3-4247-B681-5320A4CFA9DA Q33592852-21CE9C1E-1785-4ABE-BEFF-24DCFF4D5C04 Q33620546-20BCB514-6323-4D35-AEAA-A8AD6163EDC0 Q33762877-12194C1A-E650-42CA-8FA5-81DCD1E8EB11 Q33772637-4EE57BDD-1376-46E7-8D83-0D61421DED35 Q33786443-31C3BCFF-0D9F-4332-9C72-AC895E6F181F Q33896523-62B14589-3561-46EE-99B1-42724725BA22 Q34146728-AAD486EF-BA27-40E7-A930-A66C46CE2DB5 Q34174815-F83BDBF5-908A-4DE1-A791-EDA609DE5FB3 Q34180174-19A2B4DD-D67F-4E9A-8F6B-2C1A2C0DE839 Q34204325-2A10E043-025E-4D74-B641-04BC6A3B7DEE Q34230556-03F45550-927E-47A6-9FF0-964C6FDF67E7 Q34262089-B554F048-F87A-4153-BDF2-55FCC615EE45 Q34464133-C14C7EE6-0555-4B65-86CB-8CFAB13390E3 Q34499013-914F8656-CDA8-4E87-9FEB-D0899385787C Q34527469-3518F006-FFFC-4513-AC3D-A94666C3B480 Q34531858-1F7905E2-910D-478D-B718-4DF29F13D7A4 Q34533041-F2395F8E-8DB3-43FC-A582-C0F9706A215C Q34550046-99FCF9AC-02E8-4C1C-B939-493B4E2A5116

P2860

Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.

http://www.wikidata.org/entity/Q34049077

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Antibody-mediated immunotherap ...... with SHIV suppresses viraemia.

@ast

Antibody-mediated immunotherap ...... with SHIV suppresses viraemia.

@en

Antibody-mediated immunotherap ...... with SHIV suppresses viraemia.

@nl

type

label

Antibody-mediated immunotherap ...... with SHIV suppresses viraemia.

@ast

Antibody-mediated immunotherap ...... with SHIV suppresses viraemia.

@en

Antibody-mediated immunotherap ...... with SHIV suppresses viraemia.

@nl

prefLabel

Antibody-mediated immunotherap ...... with SHIV suppresses viraemia.

@ast

Antibody-mediated immunotherap ...... with SHIV suppresses viraemia.

@en

Antibody-mediated immunotherap ...... with SHIV suppresses viraemia.

@nl

P1433

Q34049077-E79A5BD4-5539-4614-9790-ABA11AD88D4D

P1476

Q34049077-C6A8343D-BB7E-458B-A8B2-4EDDE9162C53

P2093

Q34049077-000AB686-3ED7-45D3-BF26-D292DD8D2296

Q34049077-10110B26-E016-47A9-A5DB-A62107B6A6D3

Q34049077-192F87A0-6611-4352-B7D6-0DE2F53AE049

Q34049077-1A9F909C-4A78-4327-8F10-747D061DDE6D

Q34049077-3CD71B07-87EA-41E9-83FA-D12B5EAE646C

Q34049077-7120667D-885A-4CBB-8171-E5164BB02616

Q34049077-77F71205-0B1C-46CA-A38D-579218081F8B

Q34049077-8E7055FB-F4D3-4B24-9070-029514AD2915

Q34049077-AC1AB26E-04B9-4AA5-B130-3B0B6E1B4E03

Q34049077-B4D04CE5-F87B-4C84-A2F7-453646884A78

P2860

Q34049077-0D48D88B-E2D5-4A9F-9D8A-C0273F5ECF4B

Q34049077-0E3AC247-9B37-4AE0-A2C4-8332BA1122B1

Q34049077-1CE3D558-0209-43A6-AE8A-17A09DE902AD

Q34049077-24B0E4A2-963A-4834-9A48-5C632204CFBE

Q34049077-2838EA30-487E-4156-9CDC-E4A0FED72BEA

Q34049077-2847F780-754A-4283-A401-08B76A55EDC3

Q34049077-297E3212-37ED-4BB7-87C6-8B7E066C8C72

Q34049077-55C53440-5823-469D-903C-7A47CC392229

Q34049077-6EE5D871-1B2F-4A3E-9040-5357056F5326

Q34049077-717341E4-E038-4A0C-A856-C3062DB344D3

P2888

Q34049077-1A35D114-57AF-4679-8272-211CCD45B562

P304

Q34049077-BFCF7807-166A-40BA-B85B-C353A87AEEC5

P31

Q34049077-5640865F-A26F-45DD-BF94-B27A51C95037

P356

Q34049077-845C61CF-005E-4540-97BA-6CF86810C8A4

P407

Q34049077-2EC86EE2-3D16-4924-828F-4DD7F4ED29B4

P433

Q34049077-763445CA-7099-4223-B0BD-9DFB5277F860

P478

Q34049077-DFDD84F0-1CFC-4929-826E-35C06A0B148A

P50

Q34049077-DC193F8E-65B0-40EF-A59F-FA26DB3D62DB

P577

Q34049077-E570DCF2-61BC-41DB-AE8C-CD0656FF67EC

P6179

Q34049077-ACCF7DF9-F7D6-4B08-A673-B4A0C87DFC47

P698

Q34049077-4408B82C-DBDD-4570-A358-3B5D61EFFB6C

P921

Q34049077-004E56DF-1957-458F-A812-18DBEAAE60F6

Q34049077-B5B0267C-6CEF-4695-A304-D11A4390A547

P932

Q34049077-C344F80B-F302-46BC-B4B0-C728CD25475E

P356

P1433

P1476

Antibody-mediated immunotherap ...... with SHIV suppresses viraemia.

@en

P2093

Alicia Buckler-White

http://www.w3.org/2001/XMLSchema#string

Dimiter S Dimitrov

http://www.w3.org/2001/XMLSchema#string

Florian Klein

http://www.w3.org/2001/XMLSchema#string

Hugo Mouquet

http://www.w3.org/2001/XMLSchema#string

Jeffrey D Lifson

http://www.w3.org/2001/XMLSchema#string

Malcolm A Martin

http://www.w3.org/2001/XMLSchema#string

Masashi Shingai

http://www.w3.org/2001/XMLSchema#string

Michael Piatak

http://www.w3.org/2001/XMLSchema#string

Michael Seaman

http://www.w3.org/2001/XMLSchema#string

Olivia K Donau

http://www.w3.org/2001/XMLSchema#string

P2860

A Blueprint for HIV Vaccine Discovery

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120

Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

Broad neutralization coverage of HIV by multiple highly potent antibodies

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

P2888

P304

277-280

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE12746

http://www.w3.org/2001/XMLSchema#string

P407

P433

7475

http://www.w3.org/2001/XMLSchema#string

P478

503

http://www.w3.org/2001/XMLSchema#string

P50

Michel C. Nussenzweig

P577

2013-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1029594927

http://www.w3.org/2001/XMLSchema#string

P698

24172896

http://www.w3.org/2001/XMLSchema#string

P921

P932

4133787

http://www.w3.org/2001/XMLSchema#string